Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1982 2
1983 3
1984 2
1987 1
1988 1
1989 1
1991 1
1992 3
1993 4
1994 2
1995 1
1996 4
1997 2
1998 6
1999 4
2000 8
2001 4
2002 5
2003 7
2004 4
2005 8
2006 5
2007 4
2008 9
2009 2
2010 6
2011 7
2012 10
2013 8
2014 14
2015 16
2016 12
2017 6
2018 5
2019 5
2020 14
2021 6
2022 10
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Extrahepatic Bile Duct Carcinoma"
Page 1
Ampullary cancer: an overview.
Ahn DH, Bekaii-Saab T. Ahn DH, et al. Am Soc Clin Oncol Educ Book. 2014:112-5. doi: 10.14694/EdBook_AM.2014.34.112. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857067 Free PMC article. Review.
They arise from the ampullary complex, distal to the confluence of the common bile and pancreatic duct (Fig. 1). In contrast to other periampullary malignancies, true ampullary cancers present earlier in their disease course with symptoms that result from biliary ob …
They arise from the ampullary complex, distal to the confluence of the common bile and pancreatic duct (Fig. 1). In contrast t …
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. Ben-Josef E, et al. J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11. J Clin Oncol. 2015. PMID: 25964250 Free PMC article. Clinical Trial.
PURPOSE: The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. ...Median overall survival was 35 months (R0, 34 months; R1, 35 months). Local, distant, and combined relapse occurred in 14, 24, …
PURPOSE: The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknow …
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Hong TS, et al. J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14. J Clin Oncol. 2016. PMID: 26668346 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: In this single-arm, phase II, multi-institutional study, 92 patients with bi …
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) an …
Radiation therapy in cholangiocellular carcinomas.
Brunner TB, Seufferlein T. Brunner TB, et al. Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):593-602. doi: 10.1016/j.bpg.2016.08.003. Epub 2016 Aug 24. Best Pract Res Clin Gastroenterol. 2016. PMID: 27644907 Review.
The SWOG-S0809 trial regimen of chemoradiotherapy which was tested in extrahepatic cholangiocarcinoma and in gallbladder cancer can currently be regarded as highest level of evidence for this indication. ...Nevertheless, in general cholangiocarcinoma is an orphan di …
The SWOG-S0809 trial regimen of chemoradiotherapy which was tested in extrahepatic cholangiocarcinoma and in gallbladder cance …
Approaches and Outcomes to Distal Cholangiocarcinoma.
Lee RM, Maithel SK. Lee RM, et al. Surg Oncol Clin N Am. 2019 Oct;28(4):631-643. doi: 10.1016/j.soc.2019.06.014. Surg Oncol Clin N Am. 2019. PMID: 31472910 Review.
Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. ...Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trial …
Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective trea …
Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma.
McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW 3rd, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. McMillan RR, et al. Am J Transplant. 2022 Mar;22(3):823-832. doi: 10.1111/ajt.16906. Epub 2021 Dec 27. Am J Transplant. 2022. PMID: 34856069 Free article.
Our center developed a protocol for neoadjuvant therapy and LT for patients with locally advanced, unresectable iCCA in 2010. Patients undergoing LT were required to demonstrate disease stability for 6 months on neoadjuvant therapy with no extrahepatic disease. ...T …
Our center developed a protocol for neoadjuvant therapy and LT for patients with locally advanced, unresectable iCCA in 2010. Patient …
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A, Brandi G. Rizzo A, et al. Cancer Treat Res Commun. 2021;27:100354. doi: 10.1016/j.ctarc.2021.100354. Epub 2021 Mar 16. Cancer Treat Res Commun. 2021. PMID: 33756174 Free article. Review.
Biliary tract cancers (BTCs) comprise a heterogenous group of aggressive and rare malignancies arising in the bile duct outside or within the liver. BTCs include cholangiocarcinoma (CCA), gallbladder cancer (GBC) and ampulla of Vater cancer (AVC); according to the " …
Biliary tract cancers (BTCs) comprise a heterogenous group of aggressive and rare malignancies arising in the bile duct outsid …
Benefits and limitations of middle bile duct segmental resection for extrahepatic cholangiocarcinoma.
Akita M, Ajiki T, Ueno K, Tsugawa D, Tanaka M, Kido M, Toyama H, Fukumoto T. Akita M, et al. Hepatobiliary Pancreat Dis Int. 2020 Apr;19(2):147-152. doi: 10.1016/j.hbpd.2020.01.002. Epub 2020 Jan 30. Hepatobiliary Pancreat Dis Int. 2020. PMID: 32037277
BACKGROUND: Pancreaticoduodenectomy (PD) is a standardized strategy for patients with middle and distal bile duct cancers. The aim of this study was to compare clinicopathological features of bile duct segmental resection (BDR) with PD in patients with …
BACKGROUND: Pancreaticoduodenectomy (PD) is a standardized strategy for patients with middle and distal bile duct cancers. The …
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
Sapisochin G, Ivanics T, Heimbach J. Sapisochin G, et al. Hepatology. 2022 Feb;75(2):455-472. doi: 10.1002/hep.32258. Epub 2022 Jan 6. Hepatology. 2022. PMID: 34859465 Review.
The second scenario is patients with locally advanced iCCA, but where the extent of LR would be too extensive to be feasible. Preliminary single-center reports have described LT in a selected group of patients with locally advanced tumors who have responded to neoad …
The second scenario is patients with locally advanced iCCA, but where the extent of LR would be too extensive to be feasible. Prelimi …
Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects.
Nanashima A, Hiyoshi M, Imamura N, Yano K, Hamada T, Kai K. Nanashima A, et al. Curr Oncol. 2021 Oct 11;28(5):4067-4079. doi: 10.3390/curroncol28050345. Curr Oncol. 2021. PMID: 34677263 Free PMC article. Review.
The therapeutic and diagnostic modalities of light are well known, and derivative photodynamic reactions with photosensitizers (PSs), specific wavelengths of light exposure and the existence of tissue oxygen have been developed since the 20th century. Photodynamic therapy (PDT) i …
The therapeutic and diagnostic modalities of light are well known, and derivative photodynamic reactions with photosensitizers (PSs), specif …
211 results